Extranuclear ERα is associated with regression of T47D PKCα-overexpressing, tamoxifen-resistant breast cancer

BACKGROUND: Prior to the introduction of tamoxifen, high dose estradiol was used to treat breast cancer patients with similar efficacy as tamoxifen, albeit with some undesirable side effects. There is renewed interest to utilize estradiol to treat endocrine resistant breast cancers, especially since...

Descripción completa

Detalles Bibliográficos
Autores principales: Perez White, Bethany, Molloy, Mary Ellen, Zhao, Huiping, Zhang, Yiyun, Tonetti, Debra A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3661391/
https://www.ncbi.nlm.nih.gov/pubmed/23634843
http://dx.doi.org/10.1186/1476-4598-12-34

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3661391/
https://www.ncbi.nlm.nih.gov/pubmed/23634843
http://dx.doi.org/10.1186/1476-4598-12-34

Ejemplares similares